RxDoctor Payments Data

Simona Treidler, MD

Neurology · Stony Brook, NYNPI 1376888008

Payments from drug & device makers

$64,369in general payments, 2019–2025

Across 90 payments — averaging $715.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$33K
  • Novartis$15K
  • PTC Therapeutics, Inc.$15K
  • Tanabe Pharma America, Inc.$507
  • Amylyx Pharmaceuticals, Inc.$271
  • ITF Therapeutics LLC$183
  • plus $647 from 11 others

What the payments were for

  • Food & beverage$1,71899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$64,369 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$218,155
Medicare patients
428
Services billed
1,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone142$1,910,657
NexviazymeAvalglucosidase Alfa-Ngpt13$503,208
EvrysdiRisdiplam16$420,379
Gamunex-CImmune Globul G/Gly/Iga Avg 4671$378,727
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5020$373,479
RelyvrioSod Phenylbutyrat/Taurursodiol29$366,584
GammakedImmune Globul G/Gly/Iga Avg 4614$281,010
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$271,713
EmflazaDeflazacort17$148,397
NuedextaDextromethorphan Hbr/Quinidine63$112,872
Riluzole181$27,335
Repatha SureclickEvolocumab20$13,412
Pyridostigmine Bromide46$9,133
Repatha SyringeEvolocumab22$8,428
Praluent PenAlirocumab15$8,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiNexviazyme$65$503,20813 claims
Genentech USA, Inc.Evrysdi$35$420,37916 claims
CSL BehringPrivigen$20$373,47920 claims
Amylyx Pharmaceuticals, Inc.Relyvrio$271$366,58429 claims
PTC Therapeutics, Inc.Emflaza$14,580$148,39717 claims
Avanir Pharmaceuticals, Inc.Nuedexta$22$112,87263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →